BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 23970345)

  • 1. Progesterone protects ovarian cancer cells from cisplatin-induced inhibitory effects through progesterone receptor membrane component 1/2 as well as AKT signaling.
    Zhu X; Han Y; Fang Z; Wu W; Ji M; Teng F; Zhu W; Yang X; Jia X; Zhang C
    Oncol Rep; 2013 Nov; 30(5):2488-94. PubMed ID: 23970345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of ovarian cancer cell viability and sensitivity to cisplatin by progesterone receptor membrane component-1.
    Peluso JJ; Liu X; Saunders MM; Claffey KP; Phoenix K
    J Clin Endocrinol Metab; 2008 May; 93(5):1592-9. PubMed ID: 18319313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progesterone receptor membrane component-1 regulates the development and Cisplatin sensitivity of human ovarian tumors in athymic nude mice.
    Peluso JJ; Gawkowska A; Liu X; Shioda T; Pru JK
    Endocrinology; 2009 Nov; 150(11):4846-54. PubMed ID: 19797399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progestin and AdipoQ Receptor 7, Progesterone Membrane Receptor Component 1 (PGRMC1), and PGRMC2 and Their Role in Regulating Progesterone's Ability to Suppress Human Granulosa/Luteal Cells from Entering into the Cell Cycle.
    Sueldo C; Liu X; Peluso JJ
    Biol Reprod; 2015 Sep; 93(3):63. PubMed ID: 26203174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of let-7/miR-98 microRNAs in the regulation of progesterone receptor membrane component 1 expression in ovarian cancer cells.
    Wendler A; Keller D; Albrecht C; Peluso JJ; Wehling M
    Oncol Rep; 2011 Jan; 25(1):273-9. PubMed ID: 21109987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro inhibition of SKOV-3 cell migration as a distinctive feature of progesterone receptor membrane component type 2 versus type 1.
    Albrecht C; Huck V; Wehling M; Wendler A
    Steroids; 2012 Dec; 77(14):1543-50. PubMed ID: 23064006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PGRMC1-dependent autophagy by hyperoside induces apoptosis and sensitizes ovarian cancer cells to cisplatin treatment.
    Zhu X; Ji M; Han Y; Guo Y; Zhu W; Gao F; Yang X; Zhang C
    Int J Oncol; 2017 Mar; 50(3):835-846. PubMed ID: 28197632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dominant role of nuclear progesterone receptor in the control of rat periovulatory granulosa cell apoptosis.
    Friberg PA; Larsson DG; Billig H
    Biol Reprod; 2009 Jun; 80(6):1160-7. PubMed ID: 19208546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells.
    Asselin E; Mills GB; Tsang BK
    Cancer Res; 2001 Mar; 61(5):1862-8. PubMed ID: 11280739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PGRMC2, a yet uncharacterized protein with potential as tumor suppressor, migration inhibitor, and regulator of cytochrome P450 enzyme activity.
    Wendler A; Wehling M
    Steroids; 2013 Jun; 78(6):555-8. PubMed ID: 23276631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Par-4 downregulation confers cisplatin resistance in pancreatic cancer cells via PI3K/Akt pathway-dependent EMT.
    Tan J; You Y; Xu T; Yu P; Wu D; Deng H; Zhang Y; Bie P
    Toxicol Lett; 2014 Jan; 224(1):7-15. PubMed ID: 24144893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways.
    Liu HZ; Yu C; Yang Z; He JL; Chen WJ; Yin J; Li WM; Liu HT; Wang YX
    Mol Med Rep; 2011; 4(5):985-92. PubMed ID: 21687949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic effects of suberoylanilide hydroxamic acid combined with cisplatin causing cell cycle arrest independent apoptosis in platinum-resistant ovarian cancer cells.
    Ong PS; Wang XQ; Lin HS; Chan SY; Ho PC
    Int J Oncol; 2012 May; 40(5):1705-13. PubMed ID: 22328352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberration of the PI3K/AKT/mTOR signaling in epithelial ovarian cancer and its implication in cisplatin-based chemotherapy.
    Zhang HY; Zhang PN; Sun H
    Eur J Obstet Gynecol Reprod Biol; 2009 Sep; 146(1):81-6. PubMed ID: 19540648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel.
    Mitsuuchi Y; Johnson SW; Selvakumaran M; Williams SJ; Hamilton TC; Testa JR
    Cancer Res; 2000 Oct; 60(19):5390-4. PubMed ID: 11034077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progesterone-induced apoptosis in immortalized normal and malignant human ovarian surface epithelial cells involves enhanced expression of FasL.
    Syed V; Ho SM
    Oncogene; 2003 Oct; 22(44):6883-90. PubMed ID: 14534535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein kinase C inhibitor Gö6976 augments caffeine-induced reversal of chemoresistance to cis-diamminedichloroplatinum-II (CDDP) in a human ovarian cancer model.
    Qamar L; Davis R; Anwar A; Behbakht K
    Gynecol Oncol; 2008 Sep; 110(3):425-31. PubMed ID: 18619662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells.
    Fraser M; Leung BM; Yan X; Dan HC; Cheng JQ; Tsang BK
    Cancer Res; 2003 Nov; 63(21):7081-8. PubMed ID: 14612499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Membrane-initiated effects of progesterone on proliferation and activation of VEGF in breast cancer cells.
    Neubauer H; Adam G; Seeger H; Mueck AO; Solomayer E; Wallwiener D; Cahill MA; Fehm T
    Climacteric; 2009 Jun; 12(3):230-9. PubMed ID: 19340614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness.
    Pavan S; Olivero M; Corà D; Di Renzo MF
    Eur J Cancer; 2013 Mar; 49(4):964-73. PubMed ID: 23079474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.